Purdue Pharmaceuticals, L.P.
Headquarters
One Stamford Forum
Stamford
Connecticut
06901-3431
United States
Tel: 203-588-8000
Fax: 203-588-8850
Website: http://www.purduepharma.com/
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
232 articles about Purdue Pharmaceuticals, L.P.
-
The Opioid Spoon Project Names Tufts University As First Recipient Of Their Virtual Spoon Drop Campaign Launch
3/26/2019
Tufts University receives The Opioid Spoon Project's signature Opioid Spoon, "Virtually," for their on-going financial relationship with the founders of Purdue Pharmaceuticals
-
Statement of Dr. Mortimer and Dr. Raymond Sackler Families Regarding Purdue Pharma’s Settlement with State of Oklahoma
3/26/2019
The Dr. Mortimer and Dr. Raymond Sackler families issued a statement in connection with Purdue Pharma’s settlement with the State of Oklahoma
-
Embattled Purdue Pharma has agreed to pay $270 million to settle a lawsuit brought against the company over the marketing of its opioid painkiller OxyContin, according to reports.
-
Falsified Data Forces Duke to Pay $112 Million Settlement, Other Universities Under Scrutiny as Well
3/26/2019
Duke University has agreed to pay the U.S. government more than $112 million to settle allegations that a university-associated researcher falsified claims in order to obtain funding from the National Institutes of Health and other federal agencies. -
FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the Emergency Treatment of Known or Suspected Opioid Overdose
3/13/2019
Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene HCl
-
With a major lawsuit in Oklahoma targeting Johnson & Johnson and Purdue Pharma’s involvement in the opioid epidemic starting in May, many of the legal documents are being released, with strategies and sometimes incendiary rhetoric coming to light.
-
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
3/11/2019
A Prescription Drug User Fee Act (PDUFA) date is set for December 27, 2019.
-
Imbrium Therapeutics Announces Enrollment of the First Patient in Expansion Phase of Tinostamustine Trial in Patients with Difficult-to-Treat Blood Cancers
3/5/2019
Each study arm will run separately, with results to be submitted for upcoming medical meetings.
-
As Purdue Pharma grapples with multiple lawsuits over its OxyContin pain killer, there are reports that the drugmaker is exploring bankruptcy as a legal defense mechanism.
-
Purdue Pharmaceuticals is seeking to dismiss a Massachusetts lawsuit filed by that state’s attorney general that has been highly critical of the company’s marketing of its opioid pain treatment OxyContin and has also placed blame on the company for 670 opioid-related deaths in the state since 2009.
-
Imbrium Therapeutics and TetraGenetics Announce Strategic Research Collaboration and License Option to Develop Novel Biologic Therapeutics for Pain
2/26/2019
TetraGenetics to receive up to $25 million in upfront license and FTE payments; is eligible to receive total contingent payments up to $248 million plus royalties
-
Court Documents Show Purdue’s Richard Sackler Did Not Want to Correct Misinformation About Streng...
2/22/2019
Court documents have shown how invested Richard Sackler was in the drive at Purdue Pharma to make OxyContin a success. A recent deposition that was unsealed has revealed just how far Sackler was willing to go. -
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society's Conference: Advances in Sleep and Circadian Science
2/4/2019
Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant
-
You Are Getting Very Sleepy: Eisai and Purdue Pharma Release Phase III Data on Insomnia Drug
2/4/2019
Eisai Co. and Purdue Pharma presented data at the Sleep Research Society’s Conference regarding their lemborexant for the treatment of insomnia. The meeting was held in Clearwater Beach, Florida. -
The court documents in Massachusetts reveal not only how much the family made from sales of the opioid, but also the tactics used to promote sales.
-
Purdue Pharma L.P. and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment
1/28/2019
Alivio to receive up to $14.75 million in upfront and near-term license exercise payments and is eligible to receive royalties on product sales and over $260 million in research and development milestones
-
Purdue Pharma and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment
1/28/2019
Alivio to receive up to $14.75 million in upfront and near-term license exercise payments and is eligible to receive royalties on product sales and over $260 million in research and development milestones
-
Purdue Pharma Forges Agreement With Alivio Therapeutics to Advance a Non-Opioid Pain Therapy
1/28/2019
While Purdue battles numerous lawsuits over its alleged role in the opioid crisis, the Connecticut-based company has made inroads into developing non-opioid pain treatments. -
The notorious legacy of OxyContin continues to be a major black mark against Purdue Pharmaceuticals. And that mark is only getting worse as a court case against the opioid manufacturer has revealed company officials used deceptive marketing practices to boost sales of the drug.
-
Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
1/15/2019
Eisai Co., Ltd. and Purdue Pharma L.P. today announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder.